韩啸, 张竞竞, 王洪亚, 韩正全. 雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较[J]. 蚌埠医学院学报, 2013, 37(8): 946-947,950.
    引用本文: 韩啸, 张竞竞, 王洪亚, 韩正全. 雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较[J]. 蚌埠医学院学报, 2013, 37(8): 946-947,950.
    HAN Xiao, ZHANG Jing-jing, WANG Hong-ya, HAN Zheng-quan. Comparison of raltitrexed or fluorouracil plus gemcitabine in treatment of patients with advanced breast cancer[J]. Journal of Bengbu Medical College, 2013, 37(8): 946-947,950.
    Citation: HAN Xiao, ZHANG Jing-jing, WANG Hong-ya, HAN Zheng-quan. Comparison of raltitrexed or fluorouracil plus gemcitabine in treatment of patients with advanced breast cancer[J]. Journal of Bengbu Medical College, 2013, 37(8): 946-947,950.

    雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较

    Comparison of raltitrexed or fluorouracil plus gemcitabine in treatment of patients with advanced breast cancer

    • 摘要: 目的:比较雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的临床疗效及不良反应。方法:对不同药物治疗的57例晚期乳腺癌的疗效和不良反应进行回顾分析,其中雷替曲塞联合吉西他滨治疗组(A组)31例,氟尿嘧啶联合吉西他滨组(B组)26例。A组给予雷替曲塞3 mg/m2(第1天)和吉西他滨1 000 mg/m2(第1、8天)静脉输注;B组给予氟尿嘧啶500mg/m2(第1~5天)和吉西他滨1 000 mg/m2(第1、8天)静脉输注;21 d为1个周期,连用2个周期。结果:A、B组治疗的有效率分别为38. 71%和30. 77%,差异无统计学意义(0. 05)。2组患者食欲减退、呕吐、腹泻、转氨酶升高的发生率差异均有统计意义(P0. 05~P0. 01),白细胞减少差异无统计学意义(0. 05)。结论:雷替曲塞联合吉西他滨治疗晚期乳腺癌有较好的疗效,不良反应轻,可以作为晚期乳腺癌治疗方案之一。

       

      Abstract: Objective: To compare the clinical efficacy and toxicity of raltitrexed or fluorouracil plus gemcitabine in the treatment of patients with advanced breast cancer. Methods: The curative effects and adverse reactions in 57 cases of advanced breast cancer treated by different therapies were analyzedretrospectively. Group A( 31 cases) were administered raltitrexed plus gemcitabine and group B( 26 cases) fluorouracil plus gemcitabine. Group A were given raltitrexed 3 mg /m2at day 1, and gemcitabine 1 000 mg /m2 at day 1 and day 8; group B were administered fluorouracil 500 mg /m2 from day 1 to day 5,and gemcitabine 1 000 mg /m2 at day 1 and day 8. The therapies were repeated every 21 days for two cycles. Results: The response rates of group A and group B were 38. 71% and 30. 77%, respectively. The difference was not significant between the two groups ( P > 0. 05) . The difference in the occurrence of anorexia,vomiting,diarrhea and transaminase elevation had statistical significance between the two groups( P < 0. 05 to P < 0. 01) ,and the difference in leukopenia was not obvious( P > 0. 05) . Conclusions: The therapy of raltitrexed plus gemcitabine is effective and has sight adverse reactions in treatment of advanced breast cancer, it can be used as one of the regimens for patients with advanced breast cancer.

       

    /

    返回文章
    返回